Thomas Pangia is a seasoned life science consultant and chemist with a Ph.D. in Chemistry from Johns Hopkins University and a B.S. in Chemistry from Georgia College and State University. He has six years of research experience in enzyme active site model reactivity, which enables him to assess drug/enzyme activity and estimate potential drug efficacy and market value. Thomas specializes in strategy and equity research for biotech and pharmaceutical companies, bridging the gap between technical details and non-technical audiences. He is currently a Senior Life Science Specialist at L.E.K. Consulting, where he maximizes value from products and offerings. Previously, he worked as a Life Science Specialist at L.E.K. Consulting, an Equity Research Extern at Johns Hopkins Biotech Investment Group, a Pro Bono Consultant in Pharmaceuticals at Johns Hopkins Graduate Consulting Club, and a Contributor at Seeking Alpha and The Motley Fool. Thomas has strong analytical skills for developing detailed price targets based on systematic analysis of drug development pipelines and financial structure while considering key risk factors.